Research Analysts Offer Predictions for Xencor Q2 Earnings

Xencor, Inc. (NASDAQ:XNCR) – Investment analysts at William Blair decreased their Q2 2025 earnings per share estimates for Xencor in a research report issued on Wednesday, May 7th. William Blair analyst M. Phipps now expects that the biopharmaceutical company will post earnings per share of ($0.87) for the quarter, down from their prior estimate of ($0.82). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Xencor’s current full-year earnings is ($3.68) per share. William Blair also issued estimates for Xencor’s Q3 2025 earnings at ($0.89) EPS, Q4 2025 earnings at ($0.91) EPS, FY2025 earnings at ($3.33) EPS, Q1 2026 earnings at ($0.88) EPS, Q2 2026 earnings at ($0.83) EPS, Q3 2026 earnings at ($0.81) EPS, FY2026 earnings at ($3.32) EPS, FY2027 earnings at ($3.15) EPS and FY2028 earnings at ($3.24) EPS.

Xencor (NASDAQ:XNCR) last released its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.06). The firm had revenue of $32.73 million for the quarter, compared to analyst estimates of $23.44 million. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. Xencor’s revenue was up 104.6% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.11) earnings per share.

Other equities analysts have also issued research reports about the company. StockNews.com lowered Xencor from a “hold” rating to a “sell” rating in a research report on Friday, March 14th. Wells Fargo & Company cut their price target on Xencor from $37.00 to $33.00 and set an “overweight” rating for the company in a research note on Friday, February 28th. Barclays cut their price objective on Xencor from $22.00 to $6.00 and set an “underweight” rating on the stock in a research note on Thursday, May 8th. Finally, Wedbush reissued an “outperform” rating and issued a $31.00 price objective on shares of Xencor in a research note on Wednesday, April 30th. Two analysts have rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.50.

Xencor Trading Down 7.5%

NASDAQ:XNCR opened at $8.11 on Monday. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. Xencor has a 1-year low of $7.16 and a 1-year high of $27.24. The firm has a market capitalization of $577.04 million, a price-to-earnings ratio of -2.53 and a beta of 0.99. The stock has a fifty day simple moving average of $10.63 and a 200 day simple moving average of $17.52.

Insider Activity

In other Xencor news, EVP Nancy Valente sold 4,616 shares of the business’s stock in a transaction on Friday, May 2nd. The stock was sold at an average price of $11.03, for a total value of $50,914.48. Following the transaction, the executive vice president now owns 49,169 shares of the company’s stock, valued at approximately $542,334.07. The trade was a 8.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.76% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Xencor

Several large investors have recently made changes to their positions in the company. American Century Companies Inc. lifted its stake in shares of Xencor by 21.9% during the first quarter. American Century Companies Inc. now owns 139,242 shares of the biopharmaceutical company’s stock valued at $1,482,000 after acquiring an additional 25,011 shares during the period. Aberdeen Group plc grew its holdings in shares of Xencor by 114.9% during the first quarter. Aberdeen Group plc now owns 377,112 shares of the biopharmaceutical company’s stock worth $4,012,000 after buying an additional 201,592 shares in the last quarter. Public Sector Pension Investment Board grew its holdings in shares of Xencor by 27.3% during the first quarter. Public Sector Pension Investment Board now owns 221,971 shares of the biopharmaceutical company’s stock worth $2,362,000 after buying an additional 47,662 shares in the last quarter. Nuveen LLC bought a new position in shares of Xencor during the first quarter worth about $1,715,000. Finally, Invesco Ltd. boosted its position in Xencor by 44.3% during the first quarter. Invesco Ltd. now owns 656,201 shares of the biopharmaceutical company’s stock valued at $6,982,000 after purchasing an additional 201,456 shares during the last quarter.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.